20678-82-4

Usage

Class

1-methyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one belongs to the class of benzazepines.

Molecular weight

The molecular weight of 1-methyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one is 189.25 g/mol.

Bicyclic structure

1-methyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one is a bicyclic compound.

Pharmaceutical precursor

1-methyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one is commonly used as a precursor in the synthesis of various pharmaceuticals.

Dopamine receptor agonists

1-methyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one is particularly used in the development of dopamine receptor agonists.

Therapeutic applications

1-methyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one has potential therapeutic applications for the treatment of neurological disorders and psychiatric conditions.

Industrial and research applications

1-methyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one may have other industrial and research applications due to its unique chemical properties and structure.

Upstream product

• 4424-80-0 2,3,4,5-tetrahydro-1H-1-benzo[b]azepin-2-one 
• 74-88-4 methyl iodide 
• 120530-11-2 anti-2'-methyl-1,2,3,4-tetrahydronaphthalene-1-spiro-3'-oxaziridine 
• 201230-82-2 carbon monoxide 
• 41652-73-7 N-Methyl-o-(prop-2-enyl)aniline 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 1449219-18-4 N-(2-allylphenyl)-N-methylformamide 

Downstream Products

• 72503-04-9 4-<2-(N-methyl-3-trifluoromethylbenzamido)-phenyl>butanoic acid 
• 83626-94-2 4-[2-(N-methyl-4-chloro-benzamido)-phenyl]-butyric acid 
• 72503-12-9 4-[2-(N-methyl-2,4-dichloro-benzamido)-phenyl]-butyric acid 
• 72503-54-9 2-(4-{2-[Methyl-(3-trifluoromethyl-benzoyl)-amino]-phenyl}-butyl)-malonic acid diethyl ester 
• 144583-94-8 1-methyl-8-amino-2,3,4,5-tetrahydro-1H-benzo[b]azepin-2-one 

Relevant academic research and scientific papers

3. 4 - diphenyl - 4H - 1, 2, 4 - triazole derivative and its preparation method and application (by machine translation)

The invention discloses 3, 4 - diphenyl - 4H - 1, 2, 4 - triazole derivative and its preparation method and application. In particular, the invention relates to the formula (I) structure of 3, 4 - diphenyl - 4H - 1, 2, 4 - triazole derivatives, its stereoisomers or its pharmaceutically acceptable salt, formula (I) in the definition of each substituent is as defined in the specification. These structure of novel compound with heat shock protein HSP90 inhibitory activity, can be used for treating cancer, neurodegenerative diseases, inflammatory diseases, autoimmune diseases, ischemic brain injury and the like, it has broad application prospects. (by machine translation)

Diaminophosphine oxide ligand enabled asymmetric nickel-catalyzed hydrocarbamoylations of alkenes

Chiral trivalent phosphorus species are the dominant class of ligands and the key controlling element in asymmetric homogeneous transition-metal catalysis. Here, novel chiral diaminophosphine oxide ligands are described. The arising catalyst system with nickel(0) and trimethylaluminum efficiently activates formamide C-H bonds under mild conditions providing pyrrolidones via intramolecular hydrocarbamoylation in a highly enantioselective manner with as little as 0.25% mol catalyst loading. Mechanistically, the secondary phosphine oxides behave as bridging ligands for the nickel center and the Lewis acidic organoaluminum center to give a heterobimetallic catalyst with superior reactivity.

Regioselective palladium(II)-catalyzed synthesis of five- or seven-membered ring lactones and five-, six- or seven-membered ring lactams by cyclocarbonylation methodology

2-Allylphenols react with carbon monoxide and hydrogen in the presence of catalytic quantities of a cationic palladium(II) complex [(PCy3)2Pd(H)(H2O)]+BF4- or palladium acetate and 1,4-bis(diphenylpho

ETHER DERIVATIVES HAVING 5-LIPOXYGENASE INHIBITORY ACTIVITY

The invention concerns ether derivatives of the formula I Q1?X?Ar?Q2 wherein Q1 is an optionally substituted 9-, 10- or 11-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur; X is oxy, thio, sulphinyl or sulphonyl; Ar is optionally substituted phenylene, pyridinediyl, pyrimidinediyl, thiophenediyl, furandiyl, thiazolediyl, oxazoiediyl, thiadiazoiediyl or oxadiazolediyl; and Q2 is selected from the groups of the formulae II and III: wherein R1 is hydrogen, (2-5C)alkanoyl or optionally substituted benzoyl; R2 is (l-4C)alkyl; and R3 is hydrogen or (l-4C)alkyl; or R2 and R3 are linked to form a methylene, vinylene, ethylene or trimethylene group; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

Photochemistry of 2'-substituted 1,2,3,4-Tetrahydronaphthalene-1-spiro-3'-oxaziridines. Variable-temperature 1H Nuclear Magnetic Resonance Spectroscopy of 1-Substituted 1,3,4,5-Tetrahydro-2H-1-benzazepin-2-ones

The lack of regioselectivity of photorearrangement of the title spiro-oxaziridines in wich the N-substituent is syn to the aromatic ring suggests that the first formed N-O-bond-cleaved species has a significant lifetime allowing rotation (inversion) to complete with rearrangement.The energy barrier to ring inversion of the title tetrahydro-1-benzazepin-2-ones is significantly influenced by the steric interaction between the N-substituent and the peri hydrogen atom.